Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Expands By 5.1%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 14,400 shares, an increase of 5.1% from the January 15th total of 13,700 shares. Currently, 2.6% of the company’s shares are short sold. Based on an average trading volume of 401,100 shares, the short-interest ratio is presently 0.0 days.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently raised its position in Bluejay Diagnostics stock. Anson Funds Management LP boosted its holdings in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) by 359.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 319,280 shares of the company’s stock after acquiring an additional 249,770 shares during the period. Anson Funds Management LP owned 1.93% of Bluejay Diagnostics worth $41,000 at the end of the most recent reporting period. Institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Trading Down 5.0 %

Shares of BJDX stock opened at $3.41 on Wednesday. Bluejay Diagnostics has a twelve month low of $3.03 and a twelve month high of $386.72. The stock has a market cap of $1.88 million, a price-to-earnings ratio of 0.00 and a beta of 0.46. The company’s 50-day moving average price is $3.88 and its 200-day moving average price is $6.41.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.